Lineage Cell Therapeutics (XTAE:LCTX) Change In Receivables : ₪0.47 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Change In Receivables?

Lineage Cell Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was ₪2.47 Mil. It means Lineage Cell Therapeutics's Accounts Receivable declined by ₪2.47 Mil from Dec. 2023 to Mar. 2024 .

Lineage Cell Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was ₪-1.65 Mil. It means Lineage Cell Therapeutics's Accounts Receivable increased by ₪1.65 Mil from Dec. 2022 to Dec. 2023 .

Lineage Cell Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was ₪0.28 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Lineage Cell Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2024 was 4.86.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lineage Cell Therapeutics's liquidation value for the three months ended in Mar. 2024 was ₪22.84 Mil.

Lineage Cell Therapeutics Change In Receivables Historical Data

The historical data trend for Lineage Cell Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Change In Receivables Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

3.91

-2.64

-3.16

185.79

-1.65

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															0.35	-0.89	0.02	-1.13	2.47

Lineage Cell Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.47 Mil.

Lineage Cell Therapeutics (XTAE:LCTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lineage Cell Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.284	/	5.332	*	91
=	4.86

2. In Ben Graham's calculation of liquidation value, Lineage Cell Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Lineage Cell Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	161.072	-	138.444	+	0.75 * 0.284	+	0.5 * 0
=	22.84

Lineage Cell Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.